[{"address1": "1800 El Camino Real", "address2": "Suite D", "city": "Menlo Park", "state": "CA", "zip": "94027", "country": "United States", "phone": "650 331 9090", "website": "https://www.an2therapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph S. Zakrzewski", "age": 61, "title": "Co-founder & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 77576, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric E. Easom", "age": 55, "title": "Co-founder, CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 697718, "exercisedValue": 0, "unexercisedValue": 305206}, {"maxAge": 1, "name": "Mr. Joshua  Eizen J.D.", "age": 45, "title": "Chief Legal Officer & Secretary", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 439118, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Paul  Eckburg M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 581263, "exercisedValue": 0, "unexercisedValue": 185523}, {"maxAge": 1, "name": "Dr. George Harrison Talbot FACP, M.D.", "age": 75, "title": "Co-Founder & Senior Clinical Advisor", "yearBorn": 1948, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael R. K. Alley Ph.D.", "title": "Co-Founder & Head of Biology", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lucy O. Day CPA", "age": 64, "title": "CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": 391017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sanjay  Chanda Ph.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Krause B.S., M.B.A.", "age": 48, "title": "Chief Strategy Officer", "yearBorn": 1975, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Huber", "title": "Senior Vice President of Regulatory Affairs & Quality", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.93, "open": 2.91, "dayLow": 2.86, "dayHigh": 3.04, "regularMarketPreviousClose": 2.93, "regularMarketOpen": 2.91, "regularMarketDayLow": 2.86, "regularMarketDayHigh": 3.04, "forwardPE": -1.0207613, "volume": 286371, "regularMarketVolume": 286371, "averageVolume": 370556, "averageVolume10days": 528210, "averageDailyVolume10Day": 528210, "bid": 2.95, "ask": 3.04, "bidSize": 800, "askSize": 1300, "marketCap": 87737128, "fiftyTwoWeekLow": 2.72, "fiftyTwoWeekHigh": 22.22, "fiftyDayAverage": 13.2908, "twoHundredDayAverage": 12.8397, "currency": "USD", "enterpriseValue": -36080736, "floatShares": 11361827, "sharesOutstanding": 29741400, "sharesShort": 295295, "sharesShortPriorMonth": 280320, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0099, "heldPercentInsiders": 0.25428, "heldPercentInstitutions": 0.69251, "shortRatio": 0.43, "shortPercentOfFloat": 0.0143, "impliedSharesOutstanding": 29741400, "bookValue": 4.673, "priceToBook": 0.63128614, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -59676000, "trailingEps": -2.8, "forwardEps": -2.89, "52WeekChange": -0.64328897, "SandP52WeekChange": 0.30583346, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANTX", "underlyingSymbol": "ANTX", "shortName": "AN2 Therapeutics, Inc.", "longName": "AN2 Therapeutics, Inc.", "firstTradeDateEpochUtc": 1648215000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa00a21b-8695-3bf1-94dc-fb69ab804327", "messageBoardId": "finmb_645116379", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.95, "targetHighPrice": 28.0, "targetLowPrice": 7.0, "targetMeanPrice": 20.0, "targetMedianPrice": 25.0, "recommendationMean": 2.6, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 123818000, "totalCashPerShare": 4.163, "quickRatio": 8.344, "currentRatio": 8.519, "returnOnAssets": -0.29990998, "returnOnEquity": -0.48806, "freeCashflow": -21105000, "operatingCashflow": -43858000, "financialCurrency": "USD", "trailingPegRatio": null}]